Skin treatment

A topical formulation combining glycyrrhetinic acid, citrobreu, and flaxseed oil addresses the limitations of existing atopic dermatitis treatments by providing effective anti-inflammatory and barrier repair properties, improving skin hydration and reducing side effects.

WO2024243620A1PCT designated stage expired Publication Date: 2024-12-05ARETE LABS & TECH SOLUTIONS PTY LTD

Patent Information

Application Number
PCT/AU2024/050544
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for atopic dermatitis, such as corticosteroids and UVB light therapy, have significant side effects and limited efficacy, and there is a need for a more effective and safer topical formulation to manage inflammation, itching, and skin barrier repair.

Method used

A formulation comprising glycyrrhetinic acid, citrobreu, and flaxseed oil, which are combined with other ingredients to create a topical serum, oil, or ointment that provides anti-inflammatory, antimicrobial, and antioxidant properties, enhancing skin hydration and barrier function.

Benefits of technology

The formulation effectively reduces inflammation, itching, and skin dryness, improves skin hydration, and enhances barrier repair, with a low potential for irritation and sensitization, as demonstrated by safety and efficacy testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000003_0003
    Figure IMGF000003_0003
Patent Text Reader

Abstract

A formulation and method of producing the formulation is provided, wherein the formulation comprises glycyrrhetinic acid; citrobreu; flaxseed oil; and one or more carriers, diluents and / or excipients. The formulation is suitable for use in improving or enhancing skin condition and / or is suitable for use in the prevention and / or treatment of a skin disease, disorder or condition. A particular skin disease, disorder or condition is atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] TITLE SKIN TREATMENT TECHNICAL FIELD THIS INVENTION relates to a skin treatment. More particularly, this invention relates to a formulation and / or method for improving or enhancing skin condition and / or for the treatment of a skin disease, disorder or condition such as atopic dermatitis. BACKGROUND The skin constitutes a living tissue barrier exposed to the environment that provides protection against mechanical damage, prevents excessive fluid loss while allowing regulated fluid secretion such as by perspiration , provides a barrier to pathogens and also assists with thermoregulation and sensation (e.g. sensing heat, cold, touch etc.). Thus, it is desirable to maintain the normal, healthy properties of the skin that underlie the proper functioning of the skin as a living tissue barrier. In this context, the skin can be prone to certain diseases, disorders and conditions, many of which at least partly involve inflammation, such as psoriasis and dermatitis. Skin conditions typically referred to as “dermatitis”, include contact dermatitis, stasis dermatitis, atopic dermatitis and seborrhoeic dermatitis. These conditions are characterized by pruritus (itchiness), erythema (redness), excoriation (scratches, scabs), induration (swelling) and papulation (bumpiness) of the skin. Causes can range from allergic reactions to external substances, as in contact dermatitis, to internal causes as in atopic dermatitis (such as an autoimmune cause) or a yeast infection as in seborrhoeic dermatitis. Atopic dermatitis, also known as atopic eczema, is an acute or chronic inflammation of the skin that results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood, with changing severity over the years. In children under one year of age, much of the body may be affected. As children get older, the areas on the insides of the knees and elbows are most commonly affected. In adults, the hands and feet are most commonly affected. Scratching the affected areas worsens the symptoms, and those affected have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma. The cause of atopic dermatitis is unknown but believed to involve genetics, immune system dysfunction, environmental exposures, and difficulties with the permeability of the skin. With regard to genetics, studies have shown that if one identical twin is affected, the other has an 85% chance of having the condition. Atopic dermatitis can cause considerable distress from constant itchiness, dry skin, unsightly rashes and, in the worst cases, can cause debilitation and require hospitalization. There is no known cure for atopic dermatitis. Treatments consist of moisturizing lotions, occlusive dressing for extremely dry patches, topical anti- inflammatory corticosteroids, ceramides and numbing agents. Over-the-counter strength preparations of these therapies usually have minimal effect. Prescription strength corticosteroids are the most commonly prescribed therapies but can have serious detrimental side effects such as thinning of the skin, stretch marks or eye damage of te n nec essi tatin g discon ti n uation of the t rea tment . N umb ing a ge n ts and an tihistamines provide minimal relief in the majority of moderate to severe clinical cases. S oothing emo lli ents, ph eno l, men th ol an d cam phor ca n provide som e sho r t- term re lief for mild pruritus. UVB light therapy is commonly used to treat severe case s of eczem a wi th a h ig h rate of e ffectiv en ess, al though und esirable side effe cts can o cc ur such a s an increased risk of developing skin cancer as well as undesirable phototoxic reactions. SUMMARY The invention disclosed herein is broadly directed to a formulation comprising 3 In a first aspect, the invention p rovide s a fo rm u l at ion comp rising, c onsistingessentially of or co nsisting of In a preferred embodiment, th e for mulation comprises; Suit ab ly, t he fo rmul ation is suitable for the prevention and / or treatment of a skin disease, disorder o r condition. Preferably, the skin disease, disorder or condition is atopic dermatitis. Typ i c ally , the c o ncen tr a tion of Typically, the concentration ofTypically, the concentration of In a p refer re d em bodim ent, t h e formulation is a to p ical formu lation. In one particular embodiment, the f ormulatio n is a serum. Pre fera bly, ac cord ing to this particu lar embodime n t, the concentration of Pre f e rab ly, according to this particula r em bod imen t, t he concentration of Preferably, according to this par ticular em bodiment, the concentration of In another particular embodiment, the formu lation is an oil. Preferably, according to this particular embodiment, the concentration of Preferably, according to this particular embodiment, the concentration of Preferably, according to this particular embodiment, the concentration of In yet another particular embodiment, the formulation is an ointment, preferably in the form of a gel. Pre fera bly, acco rding to this particula r e mbodiment, t he co ncen tration o f Preferably, according to this particular embodiment, the concentration of Preferably, accor di ng to this particular embodiment, the concentration of In a second aspect, the i n ven tion provides a meth od of pro ducing aformulation that includes combining: S uitab ly, the fo rm ul ation is su itab le for th e prev ention and / or trea tment of a skin diseas e, dis o r der or co ndition. Preferably, the skin disease, disorder or condition is atopic dermat itis. In a preferred em b od iment, the formulation is a topical formulation. In one p a rti cular embodiment, the formulation is a serum. In another particular embodi ment, the formulation is an oil. In yet another particular embodiment, the formulation is an ointment, preferably in the form of a gel. This aspect of the invention also relates to a formulation produced by the method of this aspect. Suitably, the formulation of this aspect is the formulation of the first aspect. In a third aspect, the invention provides a method of improving or enhancing the skin condition of a mammal, said method including the step of administering to a mammal, the formulation of the first aspect or a formulation produced by the method of the second aspect to thereby improve or enhance the skin condition of the mammal. Preferably, the mammal is a human. In a fourth aspect, the invention provides a method preventing or treating a skin disease, disorder or condition, said method including the step of administering to a mammal, the formulation of the first aspect or a formulation produced by the method of the second aspect to thereby prevent or treat the skin disease, disorder or condition of the mammal. In one embodiment, the skin disease, disorder or condition is atopic dermatitis. In one embodiment, the formulation is administered topically to the mammal. Preferably, the mammal is a human. Throughout this specification, unless otherwise indicated, "comprise", "comprises" and "comprising" are used inclusively rather than exclusively, so that a stated integer or group of integers may include one or more other non-stated integers or groups of integers. By “consisting essentially of” means that the formulation consists of the stated integers or group of integers together with one or two additional non-stated integers. It will also be appreciated that the indefinite articles "a" and "an" are not to be read as si ngu la r inde finite art icles or a s o therwi se e x cluding more than one or more than a single subject to which the indefinite article refers. Concentrations described herein are expressed as percent by weight (e.g “wt%” or “% w / w”), unless otherwise explicitly stated. T h e term “about” is used herein to refer to a tolerance or variation in a stated amount. The tolerance or variation may be no more than ± 10%, ± 9%, ± 8%, ± 7%, ± 6%,± 5%, ± 4%, ± 3%, ± 2%, ± 1% of a stated amount. DETAILED DESCRIPTION The invention disclosed herein is at least partly predicated on the discoverythat act synergistically in a formula tion for treatment of the skin. The form ulati on m a y im prove or enhance the conditi on o f the skin. In a particular embodiment , the for m ulation may treat or prevent one or more diseases, disorders or conditions of the sk in, su ch as atop icderm atitis. Accordingly, a particular aspect of the inven tion p rovides a formu lation comprising, consist ing essentially of or consisting of : In a preferred embodiment, the formulation comprises; Suitably, the formulation is suitable for the prevention and / or treatment of a skin disease, disorder or condition. The one or more diseases, disorders or conditions of the skin may include acne, eczema, dermatitis, psoriasis, rosacea, burns, wounds and ulcers although without limitation thereto. As used herein, the term “dermatitis” describes one or more skin conditions that may include dermatitis, including contact dermatitis, stasis dermatitis, atopic dermatitis and seborrhoeic dermatitis. In a particular embodiment, the skin condition is atopic dermatitis. Atopic dermatitis, also known as eczema o atopic eczema, is an acute or more typically chronic inflammation of the skin that results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thickens over time. While the condition may occur at any age, it typically starts in childhood, with changing severity over the years. In children under one year of age, much of the body may be affected. As children get older, the areas on the insides of the knees and elbows are most commonly affected. In adults, the hands and feet are most commonly affected. Scratching the affected areas worsens the symptoms, and those affected have an increased risk of skin infections. Glycyrrhetinic acid, otherwise known as enoxolone or glycyrrhetic acid, is a pentacyclic triterpenoid derivative of the beta-amyrin type obtained from the hydrolysis of glycyrrhizic acid, typically obtained from the herb liquorice. There are also synthetic chemical derivatives of glycyrrhetinic acid such as carbenoxolone, acetoxalone and an anionic NHCO(CH2)CO2K side chain derivative which replaces the -OH at position 3 of ring A. Glycyrrhetinic acid has a similar structure to hydrocortisone, but without glucocorticoid action. It has been shown to exhibit anti-inflammatory effects similar to hydrocortisone as well as antioxidative, antimicrobial and anti-itching properties. One of its actions is to inhibit 11β-hydroxysteroid dehydrogenase (11β-OHSD), an enzyme responsible for catalysing the conversion of hydrocortisone to an inactive form; as such glycyrrhetinic acid can improve the efficacy of hydrocortisone (whether applied externally or already found in the skin) and reduce negative effects of over application of steroidal products onto the skin. Glycyrrhetinic acid is also a known tyrosinase inhibitor thus reducing erythema. Glycyrrhetinic acid is believed to inhibit leukotriene (a pro-inflammatory mediator) production in the skin, which primarily helps in reducing itching but also in reducing inflammation. Glycyrrhetinic acid also directly supresses or decreases production of inflammatory cytokines (i.e. IL-6, TNF- α) to provide an anti-inflammatory and anti-redness effect. Glycyrrhetinic acid increases expression of an antioxidant enzyme HO-1 as well as inhibits lipid oxidation and inactivates free radicals thus protecting the skin from damage and thus associated effects like inflammation and itching. Glycyrrhetinic acid increases cell turnover, which helps especially in the treatment of wounds and other dermal defects that may have occurred due to scratching and the generally weak skin barrier of eczematic people. Glycyrrhetinic acid has also been shown to have antimicrobial properties against bacteria such as Staphylococcus aureus (which commonly colonizes skin with atopic dermatitis and exacerbates the condition) and other microbes, which is important due to damaged skin barriers being more prone to infection. It is also rare to encounter allergic dermatitis responses to glycyrrhetinic acid, whic h make s it su ita ble for products that need to be hypoallergenic. Preferably, the concentration of 5 10 Ci tro breu , als o known as Pro tium H eptap hyllu m Re s i n , i s a n a t ur all y o cc u r rin g plant ma terial used for i ts an ti-inflammatory, healing, antimicrobial, antioxidant and 15 chem opro tective properties. Citrobreu has been shown to inhibit Staphylococcus aureus a nd ot he r bacteria. Citrobr eu has sh ow n to have antioxi dant activity th rough free radica l sc aveng ing. Citrobreu’s anti-inflammatory properties are mainly due to triterpe nes w hic h have rin g syst em s simi lar in structu re t o anti-inflamm atory steroidal c om pound s but without the side effects of those steroids. These triterpenes 20 have be en sho wn to inhibit p roductio n o f pro-in fla mma tory med iators such as IL -6 and COX-2. Preferably, the concentration of citrobreu 25 citrobreu citrobreu 30 citrobreu Flaxseed oil, flax oil (in its edible form) or linseed oil, is a colourless to yellowish o il ob tained from the dried, ripe ne d se ed s of the fl ax pla n t (L in u m usi tati ssi mu m ) . T h e oi l is obtained by press in g , som etimes fo llowed by solvent extraction. Linseed oi l is an edi ble oil that i s a source of α -lino len ic acid , a n omega-3 fatty ac id, dou bl e- unsaturat ed lino lei c acid a nd mo nounsaturat ed oleic acid. Prefe rab ly, th e concentration of flaxse ed oil flaxseed oil or any rang e betweenthese stated va lues flaxseed oil or anyran g e b e t w e e n t h es e stated values flaxseed oil orany r a n g e b e t w e e n t h e s e s t a t e d v a l u e s . It will also be appreciated that the formulation may comprise one or more de r i v a t iv e s o r e x t r a c t s o f g l y c y r r h e t i n i c a c i d , c i t r o b reu and / o r fl axseed oil. By way of example, these may include the aforementioned synthetic derivatives of glycyrrhetinic acid, fatty acid extracts of flaxseed oil (e.g. omega-3 fatty acid enriched extracts) and / or triterpene extracts of citrobreu, although without limitation thereto. 10 As used herein, the term “ refers to a solid or liquid filler, thickener, bulking agent, emulsifier, emollient, glidant, colorant, surfactant, odorant, stabilizer, gelling a gent, p H modifier such as an acid , base or buffer, aqueous and / or organic solvent, moisturizer, exfoliant, antioxidant, preservative and / or encapsulating substance that may be safely used in topical or systemic administration. The carrier, diluents and / or excipients(s) must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not cause any adverse effects in a mammal to which the formulation is administered. More particularly, these may include pectins, stearates (e.g. magnesium stearate), vitamins, minerals, salts, alginates, starches and starch derivatives such as corn starch, hydroxypropylmethyl cellulose, microcrystalline cellulose and polyvinylpyrrolidone (PVP), dextrins, hyaluronates, organosilicones such as dimethicone, alcohols, sugars and sugar alcohols such as mannitol, gelatin, glycerin, plant extracts such as aloe vera, soybean germ extract and / or plant oils, glycols such as polyethylene glycol, talc, oils, fats and waxes. Generally, formulations may be for administration by a particular route. Suitable routes of administration include topical, oral, rectal, transmucosal, transdermal and parenteral, such as subcutaneous, intramuscular, intraperitoneal or intravenous administration. Generally, formulations may be in the form of powders, capsules, tablets, caplets, lozenges, suppositories, solutions and / or suspensions for parenteral administration, syrups, troches, poultices, transdermal patches, oils, creams, balms, gels, lotions, ointments, and / or salves, inclusive of enterically-coated, controlled release and delayed release formulations. It will also be appreciated that the formulation may further comprise one or more other biologically or therapeutically active compounds or substances, including but not limited to, anti-microbials, anti-inflammatories and / or analgesics. In one embodiment, the formulation further comprises evening primrose oil. Evening primrose oil may be at a concentration of about 0.2-5.0%, inclusive of about 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%.1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.5%, 3%, 3.5%, 4.0% and 4.5%, or any range between these stated values. Dosages are readily determined by those skilled in the art, depending on factors such as the age, gender, weight and general health of the mammal to which the formulation is administered, the severity of disease symptoms, possible side effects, co-administered drugs, regulatory guidelines and the presence or absence of co-morbidities that may affect treatment, although without limitation thereto. In a preferred embodiment, the formulation is suitable for topical administration to the skin. According to this preferred embodiment, the formulation is, or is present in or a component of, a poultice, bandage, dressing, pad, transdermal patch, oil, cream, gel, ointment, lotion, liniment, paste, balm and / or salve. In one particular embodiment, t he fo rmu la tion i s an oil . In a not her parti cul ar em bod im ent the form ulation is a s e rum. In yet ano t h er partic ular emb o diment, the f ormula tion i s a n oint me nt, preferab ly in the form o f a g el. I n a fur ther em bodim en t, the se ru m and / or the oi ntm ent further c o mprise evenin g primro se o il. In t hi s re g ard , re ferenc e is m ade to Tab les 1- 3 which provi de p ar ticular exa mple s of carriers, dilu e n ts and excipients that ma y be useful according to the present inven tion . A n o ther asp ect of th e i nvention provi des a method of pro ducing aform ulation that includes combining:

[0002] 12 Another aspect of the invention provides a method of impro ving or enhan cin g the skin condition o f a mammal, said me thod inclu ding the step of administering to a mammal, the formulation of the first aspect or a formulation produced by the method of the second aspect to thereby improve or enhance the skin condition of the mammal. In this context, by “improving or enhancing the skin condition” means facilitating one or more of the normal or desired properties of the skin. These include hydration, elasticity, coloration, oiliness, glow and smoothness, although without limitation thereto. Accordingly, the formulation may facilitate the at least partial prevention or suppression of skin dryness, inflammation, scaling, flaking, blistering, peeling, cracking, wrinkling, redness, swelling and itching, although without limitation thereto. Thus, this aspect of the invention also contemplates facilitating skin restoration and / or recovery from one or more skin diseases, disorders or conditions, without necessarily treating the one or more skin diseases, disorders or conditions. Another aspect of the invention provides a method preventing or treating a skin disease, disorder or condition, said method including the step of administering to a mammal, the formulation disclosed herein to thereby prevent or treat the skin disease, disorder or condition. As used herein, the term “treating” or “treatment’ of a subject include the administration of the formulation disclosed herein with the purpose of at least partly delaying, slowing, stabilizing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, or otherwise affecting the skin disease, disorder or condition, or a sign or symptom of the skin disease, disorder or condition. As used herein, the terms “preventing” or “prevention” are intended to refer to at least the reduction of likelihood of the risk of (or susceptibility to) acquiring a skin disease, disorder or condition. By way of example, this may include causing at least one of the clinical signs or symptoms of the skin disorder, disease or condition not to develop in a mammal that may be predisposed to the skin disease, disorder or condition but does not yet experience or display clinical signs or symptoms of the skin disease, disorder or condition. As hereinbefore described, the one or more diseases, disorders or conditions of the skin may include acne, eczema, dermatitis, psoriasis, rosacea, wounds, burns and ulcers, although without limitation thereto. In a particular embodiment, the skin disease, disorder or condition is atopic dermatitis. Suitably, the formulation is topically administered to the mammal. According to this embodiment, the formulation is, or is present in or a component of, a poultice, bandage, dressing, pad, dermal patch, oil, cream, gel, ointment, lotion, balm and / or salve or any combination of these. In this regard, reference is made to Tables 1-3 which provide particular examples of carriers, diluents and excipients that may be useful according to the present invention. In the form of an oil, serum or ointment gel. It will also be appreciated that the formulation disclosed herein may be suitable for administration to mammals such as humans or as a veterinary formulation to non-human mammals. Non-limiting examples of non-human mammals include performance animals (e.g horses), domestic pets (e.g. cats and dogs) and livestock (e.g. cattle, sheep and pigs) that may be susceptible to the skin diseases, disorders or conditions disclosed herein, or to corresponding veterinary skin diseases, disorders or conditions. Suitably, the formulation disclosed herein is suitable for administration to a human. So that the invention may be fully understood and put into practical effect, reference is made to the following non-limiting Examples. EXAMPLES EXAMPLE 1 Instant relief oil formulation Referring to Table 1, Instant Relief Oil is manufactured using one manufacturing vessel. Stage 1: 1. Phase 1 ingredients are added to the Vessel 1. 2. Phase 1 ingredients are to be heated to between 70 °C and 80 °C. 3. Heated bulk should be completely melted except for some solid parƟcles of GlycyrrheƟnic Acid. 4. HomogenizaƟon is to be performed for the bulk sample unƟl GlycyrrheƟnic Acid isfinely dispersed and bulk is homogenous. 5. Bulk is to be cooled to room temperature while mixing to ensure dispersed GlycyrrheƟnic Acid does not seƩle while the mixture builds in viscosity. 6. Quality control tests are to be performed prior to storing or dispensing product. ^ Prolonged storage especially at elevated temperatures is to be avoided before dispensing the product. EXAMPLE 2 Barrier repair serum formulation Referring to Table 2, Barrier Repair Serum is manufactured using two separate manufacturing vessels. Stage 1: Water is added to Vessel 1. Note that 10% of total product weight in water is left out for use in rinsing vessels, for use as an aid in dissolving ingredients or left out to leave room for pH adjusting ingredients. 1. Dermofeel is added to Vessel 1 and dissolved in the water with mixing. 2. GlycyrrheƟnic Acid is added andfinely dispersed using homogenizaƟon (high speed mixing). 3. Mixing is maintained unƟl stage 3 to prevent seƩling of dispersed ingredient. 4. Remainder of Phase 1 ingredients are added individually and incrementally with mixing. 5. Care is to be taken to prevent formaƟon of gel clumps orfish-eyes due to insufficient weƫng or dispersion of ingredients with gelling properƟes. 6. Contents of Vessel 1 are to be heated to between 70 °C and 80 °C. 7. Temperature to be maintained unƟl Stage 3. Stage 2: 1. In a separate vessel (Vessel 2), Phase 2 ingredients are added together. 2. Contents of Vessel 2 are to be heated to between 70 °C and 80 °C with mixing. 3. All solids are expected to melt or be fully incorporated through mixing in order to form a clear homogenous oil-soluble liquid. 4. Temperature is to be maintained unƟl stage 3. Stage 3: 1. Phase 2 ingredients are to be slowly added to Vessel 1 while homogenizing. 2. HomogenizaƟon is to be maintained unƟl an opaque white and fully homogenous emulsion is formed. 3. Mixture is slowly cooled to room temperature while mixing to prevent any phase separaƟon due to temperature differenƟals. Stage 4: 1. Phase 3 ingredients are added sequenƟally into Vessel 1 while homogenizing. 2. HomogenizaƟon is to be maintained unƟl Phase 3 ingredients are deemed to be fully incorporated into the bulk mixture and the bulk mixture is homogenous. Stage 5: 1. Samples are to be taken from the bulk to conduct pH measurements. 2. Based on pH measurements and calculaƟons from the sample, citric acid or sodium hydroxide soluƟons are to be added to adjust the bulk to the appropriate pH of 5 to 6. 3. Previously leŌ out water is to be used to make up any missing weight from the bulk mixture. 4. Bulk is to be homogenized to ensure the bulk mixture and added water are fully incorporated together. 5. Quality control tests are to be performed prior to storing or dispensing product. EXAMPLE 3 Intensive ointment gel formulation Referring to Table 3, Intensive Ointment Gel is manufactured using two separate manufacturing vessels. Stage 1: 1. Phase 1 ingredients are added to the same vessel (Vessel 1) and heated to between 60 °C and 70 °C. 2. Mixture of Phase 1 ingredients are mixed unƟl a fully homogenous organic gel is formed. 3. Mixture is leŌ mixing while maintaining temperature unƟl Stage 3 to prevent any separaƟon of gel. Stage 2: 5. In a separate vessel (Vessel 2), coconut oil is added and heated to between 60 °C and 70 °C. ^ Temperature is to be maintained aŌer each addiƟonal ingredient. ^ Drops in temperature due to the addiƟon of room temperature ingredients are to be minimized by incremental addiƟon of other ingredients. 6. GlycyrrheƟnic Acid is added to the vessel and homogenized unƟlfinely dispersed and no longer visible as discrete parƟcles. ^ HomogenizaƟon or regular speed mixing is to be maintained unƟl end of stage to prevent seƩling of dispersed GlycyrrheƟnic Acid. 7. Citrobreu is added to the vessel unƟl fully incorporated. Maintained mixing and heaƟng will result in resin melƟng and being incorporated into the mixture. 8. Remaining ingredients in Phase 2 are added individually and incrementally resulƟng in a homogenous liquid mixture. 9. Mixture is leŌ mixing while maintaining temperature unƟl Stage 3 begins. Stage 3: 1. The mixture from Stage 2 is to be streamed slowly into Vessel 1 while mixing in order to fully incorporate liquids into the exisƟng gel structure forming a homogenous gel. 2. The completed mixture is leŌ mixing unƟl cooled to room temperature. 3. Quality control tests are to be performed prior to storing or dispensing product. EXAMPLE 4 Safety testing The serum and ointment gel were tested for safety. The study was conducted single blind using 107 adult male and female subjects. 50% of the subjects were self- assessed as eczema prone. The serum and ointment gel were patched under occlusive conditions using Finn chambers or equivalent occlusive patches. A total of nine induction patches worn for 47 hours or 71 hours (patching occurred Mondays, Wednesdays, and Fridays) for three weeks (a make-up day was allowed to ensure subjects had all 9 induction patches). Subjects had a rest period of 14 days. Challenge patches were applied for 48 hours, and readings were made 1 hour, and 48 hours post removal. The serum and ointment elicited no visible erythematous reactions during the induction phase of the study. There were no questionable reactions observed during the Challenge Phase (Days 38 and 40) by any of the subjects to any of the test articles. These results support the assessment that under the conditions of the study, the serum and ointment gel have demonstrated a low potential for irritation and sensitization. The oil formulation was also tested for safety. The study was conducted single blind using 106 adult male and female subjects. 50% of the subjects were self- assessed as eczema prone. The serum and ointment gel were patched under occlusive conditions using Finn chambers or equivalent occlusive patches. A total of nine induction patches worn for 47 hours or 71 hours (patching occurred Mondays, Wednesdays, and Fridays) for three weeks (a make-up day was allowed to ensure subjects had all 9 induction patches). Subjects had a rest period of 14 days. Challenge patches were applied for 48 hours, and readings were made 1 hour, and 48 hours post removal. The oil formulation elicited no visible erythematous reactions during the induction phase of the study. There were no questionable reactions observed during the Challenge Phase (Days 38 and 40) by any of the subjects to any of the test articles. These results support the assessment that under the conditions of the study, the oil demonstrated a low potential for irritation and sensitization. EXAMPLE 5 Efficacy testing Study design This study was a randomised, single-blind, single-centre study. 35 subjects were enrolled, and 34 subjects completed the study. Subjects were healthy male and female subjects, aged 18 years or older with self-perceived dry / eczema / flaky prone skin. Test Articles were coded as follows: 1 - Anti-inflammatory Barrier Repair Serum (Used as a regime) 2 - Anti-inflammatory Ointment Gel (Used as a regime) 3 - Anti-Flare Oil (Used as a regime) 4 - Negative Control (Untreated - Site 2) 5 - Positive Control (Glycerine Site - 3) Observations: - 3-day wash down from all moisturizing products with a standard bar of soap (legs and face). Corneometer® assessments of skin hydration: 3 replicates on the lower leg at baseline (i.e. prior to test article application), a single application of test articles 1 and 2 to the same test site 1 on the lower leg (2 minutes to be allowed between the application of test articles for absorption into the skin) with further Corneometer® assessments done immediately (15 minutes) after application of test article 2, and at 12 hours and at day 5 following test article application. Tewameter® assessments of Trans-epidermal water loss:1 assessment on the face at baseline (i.e. prior to test article application), application of test articles 1, 2 and 3 to the same area on the face (2 minutes to be allowed between the application of test articles for absorption into the skin) with further Tewameter® assessments done immediately (15 minutes) after application of test article 3 and at 12 hours following test article application. Subjects then used the issued products (test article 1, 2 and 3) at home, as directed and had a final Tewameter® assessment on day 5. Chromameter CR300® assessments of skin redness: 4 assessments on the face at baseline (i.e. prior to test article application), application of test articles 1, 2 and 3 to the same area on the face (2 minutes to be allowed between the application of test articles for absorption into the skin) with further Chromameter CR300® assessments done immediately (15 minutes) after application of test article 3 and at 12 hours following test article application. Subjects then used the issued products (test article 1, 2 and 3) at home, as directed and had final Chromameter CR300® assessments on day 5. Photography: 10 subjects, with the most facial redness / dry / flaky / eczema at baseline had professional high resolution clinical photographic images taken of their face (left, right and front aspects) at baseline (i.e. prior to test article application) and at the end of the study on day 5. The following equipment and settings were used to capture the images: • Camera: Nikon d850 • Lens: Nikon 105mm Macro Lens • All Images shot on camera are raw at ISO 125, 1 / 125th @ F18-F22 • Flash Lighting: 2 X Soft box @135W 2x Elincrom D-Lite RX One at 2.8 synced with a remote trigger. Self-perception questionnaire (SPQ): This was completed immediately (within 1 hour) and at 12 hours following the first test article application and on day 5. Duration of study: 3 days – Washout Phase 5 days – Active Phase Study procedure Study Day 1: (following Pre-treatment) Prior to application of the test article, the test lower leg were wiped with a soft tissue. Three readings were made at test sites 1, 2 and 3 on the lower leg using the probe attachment of the Corneometer®. Between each assessment, the Corneometer® probe attachment was pressed onto a dry tissue. The next assessment was not performed until a value of 5 or less was displayed by the instrument.50 μl of test article 1 was applied to one of the 25 cm2 test sites on the lower leg and was spread evenly across the area using a gloved finger.2 minutes were allowed for the test article to be absorbed into the skin.50 μl of test article 2 was then applied to the same 25 cm2 test site on the lower leg and was spread evenly across the area using a gloved finger. Another test site on the lower leg (negative control – Site 2) remained untreated, and another test site on the lower leg (humectant positive control – Site 3) was dosed with glycerine. Products were applied to the test sites in a randomised order. Three measurements were then made using the probe attachment of the Corneometer® at test sites 1, 2 and 3 on the lower leg immediately (15 minutes) following application of the test articles. Between each assessment, the probe attachment of the Corneometer® was pressed onto a dry tissue. The next assessment was not performed until a value of 5 or less was displayed by the instrument. 10 subjects with the most facial redness / dry / flaky / eczema at baseline had professional high resolution clinical photographic images taken of their face (left, right and front aspects) at baseline (i.e. prior to test article application to the face). Four Chromameter® readings were taken (at the most affected area of facial redness / dry / flaky / eczema of each cheek, chin and centre of the forehead) and one Tewameter® reading was taken (at the most affected area of facial redness / dry / flaky / eczema of the face) using the probe attachments at baseline (i.e. prior to test article application to the face). Subjects then applied test article 1 followed by test article 2 followed by test article 3 to their face as directed, following the sponsors usage instructions. (2 minutes were allowed between the application of each test article for it to be absorbed into the skin. Immediately (15 minutes) after the application of test article 1, 2 and 3 to the face, four Chromameter® readings were taken (at the same areas as baseline) using the probe attachment. Immediately (15 minutes) after the application of test article 1, 2 and 3 to the face, one Tewameter® reading was also taken (from the same area as baseline). For the immediate (15 minutes) post-application Tewameter® measurement, the face was wiped first with a dry tissue to remove any excess product then the measurement was taken, subjects then reapplied test articles 1, 2 and 3 to their face as directed before, following the sponsors usage instructions. Following the immediate (15 minute) timepoint assessments subjects completed a self-perception questionnaire (within 1 hour following the first test article application). Subjects then were able to leave the test facility until the next assessment. 12-hour assessments: Subjects returned to the testing facility 12-hours after the first test article application and sat resting for a period of at least 30 minutes in a controlled environment at a temperature of 22oC ±2oC and at a relative humidity of 45% ± 5%. Toilet visits were allowed but subjects must have been in the controlled environment for at least 30 minutes prior to any assessments being performed. Three measurements were made using the probe attachment of the Corneometer® at test sites 1, 2 and 3 on the lower leg. Between each assessment, the probe attachment of the Corneometer® was pressed onto a dry tissue. The next assessment was not performed until a value of 5 or less was displayed by the instrument. Four Chromameter® readings and one Tewameter® reading (same areas as baseline) were taken from the face using the probe attachments and subjects completed a self- perception questionnaire. Subjects were then issued with the products (test article 1, 2 and 3) to use at home on their face, as directed for the duration of the study. A subject information sheet, including the usage and storage instructions of the test articles were provided. Day 5 assessments: Subjects returned to the testing facility on study Day 5 and sat for a period of at least 30 minutes in a controlled environment at a temperature of 22oC ± 2oC and at a relative humidity of 45% ± 5%. Toilet visits were allowed but subjects must have been in the controlled environment for at least 30 minutes prior to any assessments being performed. Three measurements were made using the probe attachment of the Corneometer® at test sites 1, 2 and 3 on the lower leg. Between each assessment, the probe attachment of the Corneometer® was pressed onto a dry tissue. The next assessment was not performed until a value of 5 or less was displayed by the instrument. Four Chromameter® readings and one Tewameter® reading (same areas as baseline) was taken from the face using the probe attachments and subjects completed a self-perception questionnaire. The same 10 subjects who had baseline professional high resolution clinical photographic images taken of their face (left, right and front aspects) had images taken again. Results There were no adverse reactions reported. Mean Corneometer® values, between-treatment t-test analyses in comparison to the mean score for Site 2 (untreated / control) are presented in Tables 4 and 5. As can be seen from the data, the test articles produced statistically significantly higher Corneometer® values (p <0.05) than the Negative Control at all time points following post treatment times of immediate (15 minutes), 12-hours and Day 5. Mean Tewameter® values, within-treatment t-test analyses in comparison to the mean baseline (untreated) score are presented in Tables 6 and 7. As can be seen from the data, the test articles produced statistically significantly lower Tewameter® values (p <0.05) than the baseline (untreated) value at all time points following post treatment times of immediate (15 minutes) 12-hours and Day 5. Mean Chromameter a* values, within-treatment t-test analyses in comparison to the mean baseline (untreated) score are presented in Tables 8-15. As can be seen from the data, the test articles produced statistically significantly lower Chromameter a* values (p <0.05) than the baseline (untreated) value at all time points following post treatment times of immediate (15 minutes) 12-hours and Day 5. Conclusions The data from the Corneometer® measurements demonstrate there were no statistically significant differences (p> 0.05) between the test site and the untreated site prior to application of the test articles which confirms the validity of the study. After a single application, test articles 1 and 2 (applied as a regime) produced statistically significant hydration (moisturisation) of the skin (p <0.05) when compared to the untreated site for all of the timepoints up to and including Day 5. The data from the Tewameter® measurements demonstrate test articles 1, 2 and 3 (applied as a regime) performed statistically significantly at improving the skin barrier function measured via trans epidermal water loss readings of the skin (p <0.05) when compared to baseline (untreated site) for all of the timepoints; up to and including 12- hours and within 5 days of test article usage. The data from the Chromameter CR300® a* measurements demonstrate test articles 1, 2 and 3 (applied as a regime) performed statistically significantly at reducing skin redness when compared to baseline (untreated site) for all of the timepoints; up to and including 12-hours and within 5 days of test article usage. Referring to Table 16, data from the self-perception questionnaire “immediately” (within one hour) following the first application of test articles 1, 2 and 3 (applied as a regime) to the face show the test articles performed highly favourably to Table 16 questions 1 and 8 (>80% of subjects selected top 2 responses) and favourably to questions 4, 7, 9 and 10, (>50% of subjects selected top 2 responses). Data from the self-perception questionnaire 12 hours following the first application of test articles 1, 2 and 3 (applied as a regime)to the face show the test articles performed highly favourably to Table 16 questions 1, 4, 7, 8, 9 and 10 (>80% of subjects selected top 2 responses) and favourably to questions 2, 3, 5 and 6 (>50% of subjects selected top 2 responses). Data from the self-perception questionnaire on Day 5 following use of test articles 1, 2 and 3 (applied as a regime) to the face for 5 days show the test articles performed highly favourably to the majority of questions 1, 3, 4, 5, 6, 7, 8, 9 and 10 (>80% of subjects selected top 2 responses) and favourably to question 2 (>50% of subjects selected top 2 responses). Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. It will therefore be appreciated by those of skill in the art that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the present invention. All computer programs, algorithms, patent and scientific literature referred to herein is incorporated herein by reference.

[0003] TABLES Table 1: Instant Relief Oil - Ingredients and Manufacturing Ingredient w / w% Phase # Flaxseed Oil 90% 1 Glycyrrhetinic Acid 2% 1 Citrobreu (Protium Heptaphyllum Resin) 2% 1 Bisabolol 2% 1 Tocopherol in Soybean Oil 2% 1 Candelilla Wax 2% 1 Table 2: Barrier Repair Serum - Ingredients and Manufacturing Ingredient w / w% Phase # Aqua 1 Sodium Phytate 1 Glycyrrhetinic Acid 0.5% 1 Bio-saccharide Gum-1 solution 1 Sodium Hyaluronate 1 Konjac Mannan Gel Powder 1 Cetearyl Olivate and Sorbitan Olivate 2 Stearyl Alcohol, Cetyl Alcohol, Myristyl Alcohol, 2 Arachidyl Alcohol Blend Shea Butter 2 Castor Seed Oil, Soybean Germ Extract, Corn Starch, 2 Silica Blend Coconut Oil 2 Sunflower Oil 2 Evening Primrose Oil 1% 2 Flaxseed Oil 1% 2 Ceramide 3 2 Rosehip Oil 2 Citrobreu (Protium Heptaphyllum Resin) 1% 2 Dimethicone 350 CST 3 Dimethicone / Dimethiconol 3 Tocopherol in Soybean Oil 3 Stabil Zero (Self Preserving Anti-Microbial Solution) 3 Spectrastat (Self Preserving Anti-Microbial Solution) 3 Citric Acid Solution q.s. 4 Sodium Hydroxide Solution q.s. 4 Water q.s. 4 Table 3: Ointment Gel - Ingredients and Manufacturing Ingredient w / w% Phase # Castor Seed Oil, Soybean Germ Extract, Corn Starch, 1 Silica Blend Safflower Oil, Olive Oil, Beeswax, Tocopherol Blend 1 Coconut Oil 2 Glycyrrhetinic Acid 1% 2 Citrobreu (Protium Heptaphyllum Resin) 1% 2 Sunflower Oil 2 Evening Primrose Oil 2 Rosehip Oil 2 Tamanu Oil 2 Tocopherol in Soybean Oil 2 Bisabolol 2 Flaxseed Oil 5% 2 TABLE 4 – MEAN CORNEOMETER® VALUES FOR THE TEST ARTICLES AND CONTROLS Mean data Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum & anti- 26.6 55.7 51.6 34.0 inflammatory ointment gel Negative control (untreated) 26.5 26.8 25.7 22.6 Positive control (Glycerin) 26.7 101.9 96.8 76.8 TABLE 5 – STATISTICAL ANALYSES FOR THE TEST ARTICLES VERSUS THE NEGATIVE CONTROL Statistical analyses (versus Negative control) Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum & anti-0.752.44E-16 1.12E-15 2.50E-08 inflammatory ointment gel Positive control (Glycerin) 0.521.26E-24 1.74E-24 2.47E-23SIGNIFICANT IF P<0.05 TABLE 6 – MEAN Tewameter® VALUES FOR THE TEST ARTICLES Mean data Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti-13.6110.83 11.13 9.75 inflammatory ointment gel and anti-flare oil TABLE 7 – Tewameter® STATISTICAL ANALYSES FOR THE TEST ARTICLES VERSUS BASELINE (UNTREATED) Statistical analyses (versus untreated) Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti- 9.12E-20 2.43E-18 4.28E-24 inflammatory ointment gel and anti-flare oil TABLE 8 – MEAN Chromameter® a* VALUES FOR THE TEST ARTICLES Left cheek Mean data Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti-7.967.82 7.01 5.53 inflammatory ointment gel and anti-flare oil TABLE 9 – MEAN Chromameter® a* VALUES FOR THE TEST ARTICLES Right cheek Mean data Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti-7.917.78 7.00 5.36 inflammatory ointment gel and anti-flare oil TABLE 10 – MEAN Chromameter® a* VALUES FOR THE TEST ARTICLES Chin Mean data Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti-7.957.81 7.05 5.54 inflammatory ointment gel and anti-flare oil TABLE 11 – MEAN Chromameter® a* VALUES FOR THE TEST ARTICLES Forehead Mean data Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti-7.927.79 7.06 5.49 inflammatory ointment gel and anti-flare oil TABLE 12 – Chromameter® a* STATISTICAL ANALYSES FOR THE TEST ARTICLES VERSUS BASELINE (UNTREATED) Left cheek Statistical analyses (versus untreated) Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti- 9.93E-15 1.22E-20 1.15E-25 inflammatory ointment gel and anti-flare oil

[0004] TABLE 13 – Chromameter® a* STATISTICAL ANALYSES FOR THE TEST ARTICLES VERSUS BASELINE Right cheek Statistical analyses (versus untreated) Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti- 1.41E-13 2.35E-18 2.29E-28 inflammatory ointment gel and anti-flare oil TABLE 14 – Chromameter® a* STATISTICAL ANALYSES FOR THE TEST ARTICLES VERSUS BASELINE Chin Statistical analyses (versus untreated) Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti- 3.46E-15 6.01E-19 8.28E-25 inflammatory ointment gel and anti-flare oil TABLE 15 – Chromameter® a* STATISTICAL ANALYSES FOR THE TEST ARTICLES VERSUS BASELINE Forehead SIGNIFICANT IF P<0.05 Statistical analyses (versus untreated) Timepoint 0 IMM 12 hr Day 5 Anti-inflammatory barrier repair serum, anti- 7.26E-13 2.83E-20 1.74E-24 inflammatory ointment gel and anti-flare oil

[0005] Table 16: Testing results immediately after topical administration of formulation immediately, after 12 hrs and after 5 days. Immediately 12 hrs 5 days Improved skin hydration 91.18 100 100 Improved skin glow 17.65 52.94 64.71 Improved skin elasticity 8.82 55.88 82.35 Reduction in itchiness 64.71 88.24 97.06 Reduction in redness 41.18 76.47 88.24 Reduction in inflammation 23.53 52.94 97.06 Reduction in dry or flaky skin 76.47 97.06 100 Improved skin barrier 94.12 100 94.12 Positive skin appearance 76.47 97.06 88.24 Positive skin feel 58.82 91.18 100 .

Claims

31CLAIMS1. A formulaƟon comprising, consisƟng essenƟally of or consisƟngof:

2. The formulaƟon of Claim 1 comprising:3.

4. The formulaƟon of any preceding claim, whichis suitable fortheprevenƟonand / ortreatment of a skindisease, disorder or condiƟon.

5. The formulaƟon of Claim 4, wherein the skin disease, disorder orcondiƟon is atopic dermaƟƟs. 6.TheformulaƟonof any precedingclaimwhich issuitablefortopical administraƟon. 7.The formulaƟon ofany preceding claim, wherein the formulaƟon is anoil, serumand / or ointment gel.8.TheformulaƟonofany preceding claim, whereintheconcentraƟonofTheformulaƟon of anyprecedingclaim, wherein the concentraƟon ofThe formulaƟon of anypreceding claim the concentraƟon ofAmethod of producing a formulaƟon that includes combining:32A formulaƟon produced by the method of Claim13 or Claim 14.The method of Claim 13 or Claim 14 or the formulaƟon of Claim 15, wherein theformulaƟon is according to any one of Claims 1-12.A method of improving or enhancing the skin condiƟon of a mammal, saidmethod including the step of administering to a mammal, the formulaƟon of any one ofClaims 1-12, 15or 16, to thereby improve or enhance the skin condiƟon of the mammal.A method prevenƟng or treaƟng a skin disease, disorder or condiƟon, saidmethod including the step of administering to a mammal, the formulaƟon of any one of Claims1-12, 15 or Claim 16, to thereby prevent or treat the skin disease, disorder orcondiƟon.The method of Claim 17 or Claim 18, wherein the formulaƟon is administeredtopically.The method of Claim 18 or Claim 19, wherein the skin disease, disorder orcondiƟon is atopic dermaƟƟs.The method of any one of Claims 17-20, wherein the mammal is a human.

Citation Information

Patent Citations

  • Topical Pharmaceutical Bases for Treating Skin Conditions

    US20160051610A1

  • Skin conditioning compositions containing compounds for mimicking the effect on skin of retinoic acid

    WO2002002074A2

Cited By

  • Formulation and method for treatment of skin

    WO2026117822A1